ASCO President Dr Peter Yu Discusses Aggregating Patient, Doctor Data

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.

With deadlines looming in 2026 and 2027 for compliance with the CMS Advancing Interoperability and Improving Prior Authorization Final Rule, a survey indicates a concerning lack of readiness among payers and providers to meet the new requirements for data sharing.

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.